Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Explore Bugs as Drugs for Cancer Imaging & Therapy by studying microorganism interactions with tumors & immunity for clinical potential.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports basic and preclinical research using microorganisms for cancer imaging, therapy, or diagnostics—clinical trials not allowed.
Key Information: Updated March 31, 2025: Review the full NOFO for recent changes before applying.
Description
This opportunity, offered by the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), supports research on the use of bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the mechanisms of interaction between microorganisms, tumors, and the immune system. The goal is to explore the clinical potential of these microorganisms for cancer imaging, therapy, or diagnostics.
Projects may focus on:
- Using microorganisms as anti-tumor agents
- Activating anti-tumor immunity
- Employing microbes as delivery vehicles for treatment, diagnosis, or imaging
The program supports basic mechanistic and preclinical studies in cell culture and animal models. Multidisciplinary teams (microbiology, immunology, cancer biology) are encouraged. Clinical trials are not allowed under this opportunity.
